## EXPD: Expeditors International of Was - XLI: Industrials

### Executive Summary

No thesis match: MRS_20 0.3% below STRENGTH zone (4.0-10.0%); PEG 4.90 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($141.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Expeditors International of Washington's (NYSE:EXPD) Five-year Earnings Growth Trails the 12% YoY Shareholder Returns**
- Source: 富途牛牛 | 20251209T020928 | Neutral | Relevance: 97%
- This article analyzes Expeditors International of Washington's financial performance over the past five years, noting that while shareholders have seen average annual returns of 12%, the company's earnings per share (EPS) growth has been lower at 9.4% per year. This discrepancy suggests that while the business has made some progress, the share price growth has outpaced the fundamental earnings improvements. The article likely delves into factors contributing to this trend and what it means for investors.

**2. Morgan Stanley Maintains Expeditors International of Washington (EXPD) Underweight Recommendation**
- Source: Nasdaq | 20251208T120300 | Neutral | Relevance: 97%
-  Morgan Stanley has maintained its "Underweight" recommendation for Expeditors International of Washington (EXPD). Analysts predict a 13.61% downside with an average one-year price target of $130.85 per share, compared to its recent closing price of $151.47. The company's projected annual revenue is 12,347MM, reflecting a 10.56% increase, with a projected non-GAAP EPS of 4.30.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $95 | $90 | +6% |
| 2025-11-17 | UBS | $166 | $138 | +20% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Underweight |
| 2025-11-17 | UBS | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.93M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (-0.9%)
- Blackrock Inc.: 9.2% (-10.1%)
- State Street Corpora: 5.8% (+5.1%)
- First Eagle Investme: 4.7% (+0.0%)
- LOOMIS SAYLES & CO L: 4.3% (+1.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.2% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 4.9x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.90 signals overvaluation risk, limited margin of safety. Forward P/E 24.8x stretched relative to 2% growth. Quality metrics strong (ROE 36%, ROA 14%). Analyst sentiment positive (2 raises, avg +13%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.0B |
| Beta | 1.14 |
| 52W Range | $100.47 - $151.67 |
| Short Interest | 5.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.90 |
| Forward P/E | 24.8 |
| Current P/E | 25.1 |
| YoY Growth | 1.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 2.5% to 0.3% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.7pp (needs >4.0% for momentum thesis). MRS_5 (-1.2%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.29% (CS: 62) | Neutral |
| RSI_14 | 64.9 | Neutral |
| MACD Histogram | -0.29 | Bearish |
| vs SMA20 | 1.024x | Above |
| vs SMA50 | 1.126x | Above |
| vs SMA200 | 1.233x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $147.71
- **Stop Loss:** $141.57 (4.2% risk)
- **Target:** $153.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 81
- **Position Value:** $11,964.51
- **Portfolio %:** 11.96%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-24 (Est: $1.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.39 | $1.64 | +18.1% |
| 2025Q2 | $1.24 | $1.34 | +7.9% |
| 2025Q1 | $1.35 | $1.47 | +9.1% |
| 2024Q4 | $1.44 | $1.68 | +16.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*